

---

# Guidance for Industry

## Inhalational Anthrax (Post-Exposure) — Developing Antimicrobial Drugs

### ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Brad Leissa 301-827-2350.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**March 2002  
Clinical Antimicrobial**



# Guidance for Industry

## Inhalational Anthrax (Post-Exposure) — Developing Antimicrobial Drugs

*Additional copies are available from:  
Office of Training and Communication  
Division of Drug Information, HFD-240  
Center for Drug Evaluation and Research  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857  
(Tel) 301-827-4573  
<http://www.fda.gov/cder/guidance/index.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**March 2002  
Clinical Antimicrobial**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## TABLE OF CONTENTS

<b>I. INTRODUCTION.....</b>	<b>1</b>
<b>II. BACKGROUND .....</b>	<b>2</b>
<b>A. Disease Description.....</b>	<b>2</b>
<b>B. Histology.....</b>	<b>3</b>
<b>III. THE MONKEY MODEL — APPLICABILITY TO THE HUMAN DISEASE .....</b>	<b>4</b>
<b>IV. DRUGS EFFECTIVE IN MANAGING PATIENTS .....</b>	<b>5</b>
<b>V. INHALATIONAL ANTHRAX (POST-EXPOSURE).....</b>	<b>6</b>
<b>A. The Indication: Regulatory Synonyms.....</b>	<b>7</b>
<b>B. Chemistry .....</b>	<b>7</b>
<b>C. Preclinical Toxicology Data .....</b>	<b>7</b>
<b>D. In Vitro Microbiology Data .....</b>	<b>7</b>
<b>E. Rhesus Monkey and Other Animal Models of Efficacy .....</b>	<b>8</b>
<b>F. Clinical Pharmacology.....</b>	<b>10</b>
<b>G. Efficacy in Humans for Other Indications .....</b>	<b>11</b>
<b>H. Evidence of Long-Term Safety in Humans.....</b>	<b>11</b>
<b>I. Statistics.....</b>	<b>12</b>
<b>J. Regulatory Issues.....</b>	<b>12</b>
<b>K. Labeling.....</b>	<b>12</b>
<b>L. Postapproval Commitments and/or Requirements.....</b>	<b>12</b>
<b>VI. SUMMARY.....</b>	<b>13</b>
<b>REFERENCES.....</b>	<b>14</b>



26 **Guidance for Industry<sup>1</sup>**

27  
28 **Inhalational Anthrax (Post-Exposure)—**  
29 **Developing Antimicrobial Drugs**  
30  
31

32 This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's)  
33 current thinking on this topic. It does not create or confer any rights for or on any person and does  
34 not operate to bind FDA or the public. An alternative approach may be used if such approach  
35 satisfies the requirements of the applicable statutes and regulations.

36  
37  
38  
39 **I. INTRODUCTION**  
40

41 In response to the recent bioterrorism event involving exposure to *Bacillus anthracis*, FDA has  
42 been approached by a number of firms seeking guidance on how to develop additional therapies  
43 and ultimately to receive FDA-approved labeling for anthrax. This guidance focuses on the  
44 development of antimicrobial drugs for administration to persons who have inhaled aerosolized  
45 *Bacillus anthracis*, but who do not yet have the established disease. The treatment goal would be  
46 to prevent the development of disease in such persons following exposure to *B. anthracis* spores.  
47

48 This guidance is *not* intended to provide recommendations on how to treat the established  
49 disease, whether inhalational anthrax, gastrointestinal anthrax, or cutaneous anthrax. This  
50 guidance also does *not* address the use of other means of managing patient exposure, public  
51 health agency roles, drug stockpiles, or deployment of agents following an exposure to *B.*  
52 *anthracis*.  
53

54 This is one in a series of guidance documents intended to assist the pharmaceutical industry in  
55 the development of antimicrobial drug products for the treatment or prevention of infections.  
56 The information presented here should help applicants plan, design, conduct, and appropriately  
57 monitor the studies, including clinical studies, to collect relevant data for analysis, and perform  
58 appropriate types and numbers of analyses of study data. Before a drug can receive a labeled  
59 indication for inhalational anthrax (post-exposure), the sponsor should have extensive  
60 postmarketing experience with their drug, including, ideally, prolonged drug dosing safety  
61 information. For an intended use where large populations may be indicated to receive prolonged  
62 antimicrobial drug dosing, extensive post-marketing safety experience is needed to formulate a  
63 risk-benefit analysis between the potential benefit of effective drug therapy and the risks of  
64 inhalational anthrax spore exposure and prolonged drug dosing.

---

<sup>1</sup> This guidance has been prepared by the Office of Drug Evaluation IV and the Office of Program Initiatives, representing the Division of Anti-Infective Drug Products, the Division of Special Pathogen and Immunologic Drug Products, and the Division of Anti-Viral Drug Products in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration.

65  
66 Applications submitted to the Agency on studies conducted as recommended in this guidance  
67 should yield the information necessary for the Agency to determine whether the antimicrobial  
68 under study is safe and effective for use in persons exposed to aerosolized *B. anthracis* who do  
69 not yet have established disease. For general information on antimicrobial drug development,  
70 the reader is referred to the guidance *Developing Antimicrobial Drugs — General*  
71 *Considerations for Clinical Trials (General Considerations)*.

## 72 73 **II. BACKGROUND**

74  
75 In the fall of 2001, *B. anthracis*, the bacterium that causes anthrax, was used as a bioterrorism  
76 agent and sent through the U.S. mail, resulting in cases of cutaneous and inhalational anthrax in  
77 New York, New Jersey, the District of Columbia, Maryland, Virginia, Florida, and Connecticut.  
78 Until this time, anthrax was exceedingly rare in the United States. Approximately 220 cases of  
79 cutaneous anthrax (CDC 2000) and 18 cases of inhalational anthrax (Brachman 1980) were  
80 reported in the United States in the 20<sup>th</sup> century. Before 2001, the last reported case of  
81 inhalational anthrax occurred in 1976 (Suffin et al., 1978). More recent recognized outbreaks  
82 were reported in other parts of the world, including an outbreak in 1979, when in Sverdlovsk  
83 (currently Ekaterinburg), Russia, 66 people died of inhalational anthrax after *B. anthracis* spores  
84 were accidentally released from a Soviet military laboratory (Meselson et al., 1979). Data  
85 available from 41 autopsies have contributed to our present knowledge concerning disease  
86 pathogenesis.

87  
88 A window of opportunity for preventive therapy exists between the time of inhalation of  
89 aerosolized spores of *B. anthracis* and development of signs and symptoms of disease. Evidence  
90 from animal models and recent human experience has demonstrated use of certain antimicrobial  
91 agents *after* the inhalational exposure to *B. anthracis* spores, but *before* the development of  
92 disease symptoms can be effective in preventing the disease and reducing mortality. As a result,  
93 the Agency is encouraging the development of antimicrobial agents to be used in the event of  
94 inhalational exposure to *B. anthracis*. This guidance provides recommendations on how to  
95 develop such agents and gives examples of agents that have met approval criteria.

### 96 97 **A. Disease Description**

98  
99 Anthrax is a bacterial infection caused by the gram-positive bacillus, *B. anthracis*.  
100 A disease of antiquity, anthrax was responsible for major epidemics and mortality. The  
101 incidence of the disease declined rapidly after the etiologic role of *B. anthracis* was  
102 recognized and scientists such as Robert Koch and Louis Pasteur worked to introduce  
103 control measures and animal vaccination.

104



105 Three types of infections are recognized in humans: cutaneous, gastrointestinal, and  
106 inhalational disease. Cutaneous anthrax occurs when spores gain access through a cut or  
107 abrasion in the skin. The organisms germinate and produce toxins that result in a local  
108 reaction with swelling and eschar formation. The disease may progress to bacteremia,  
109 and mortality is reported in up to 20 percent of untreated cutaneous cases. Cutaneous  
110 anthrax can be recognized clinically, and morbidity and mortality are low with  
111 appropriate antimicrobial therapy. Gastrointestinal disease is usually associated with the  
112 ingestion of anthrax-contaminated meat. Gastrointestinal disease can be prevented  
113 through the effective inspection of livestock and meat products entering the marketplace.  
114 Inhalational anthrax follows aerosolized exposure to the spores of *B. anthracis* with  
115 subsequent germination of the spores, toxin production, and invasion of the tissues and  
116 blood stream by the organism. After a usual incubation period of 2 to 6 days, exposed  
117 individuals develop symptomatic disease with very high mortality.

118  
119 Inhalational anthrax was encountered as recently as the 19<sup>th</sup> century in industrial settings  
120 when large numbers of spores were aerosolized in certain factories (e.g., woolsorter's  
121 disease or ragpicker's disease) (Plotkin et al., 1960). Mortality for established disease,  
122 even after treatment, was 80 to 100 percent in the 20<sup>th</sup> century. These rates may change  
123 as established disease is treated in the 21<sup>st</sup> century.

## 124 **B. Histology**

125  
126  
127 Extensive edema, necrosis, and hemorrhage into affected tissues, including the  
128 mediastinal and hilar lymph nodes, the gastrointestinal tract, and the meninges  
129 characterize histopathologic changes in human anthrax. Notably, given the respiratory  
130 route of entry of the spores and deposition within the alveoli, there are only rare reports  
131 of pulmonary bacterial pneumonia, such as consolidation, and inflammation within the  
132 pulmonary parenchyma. However, pleural effusions are common.

## 133 **C. Microbiology**

### 134 *1. In vitro susceptibility testing*

135  
136  
137  
138 Currently, there are no standardized methods (e.g., disk diffusion, broth dilution, or agar  
139 dilution) for the susceptibility testing of *B. anthracis*. During the bioterrorism events of  
140 2001, the Centers for Disease Control and Prevention (CDC) evaluated the minimal  
141 inhibitory concentrations (MICs) of several antimicrobials against the causative strains of  
142 *B. anthracis* using the current National Committee for Clinical Laboratory Standards  
143 (NCCLS) broth dilution method (NCCLS 2000). The suitability of the current NCCLS  
144 broth dilution testing method for susceptibility testing of drugs against *B. anthracis* is  
145 under evaluation by the FDA, CDC, and NCCLS. Interpretive criteria by which an  
146 isolate of *B. anthracis* may be defined as susceptible or resistant to a particular  
147 antimicrobial have not been determined. The Agency recommends that applicants  
148 contact the NCCLS for the latest information on susceptibility testing of *B. anthracis*.<sup>2</sup>

---

<sup>2</sup> NCCLS can be contacted at [www.NCCLS.org](http://www.NCCLS.org).

149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195

2. *Mechanisms of resistance*

The isolates of *B. anthracis* used during the Fall 2001 bioterrorism episodes have not demonstrated high minimum inhibitory concentrations (MICs) to any of the antimicrobials tested. However, the existing literature on the susceptibility of *B. anthracis* suggests that some strains may be penicillin resistant (Lightfoot et al., 1990). In addition, the potential for multi-drug resistant strains of *B. anthracis* exists (Inglesley et al., 1999). Russian scientists claim to have produced a vaccine strain of *B. anthracis* that is resistant to penicillin and doxycycline (Stepanov et al., 1996). The potential for drug resistance supports the study of several classes of antimicrobials to prevent the development of inhalational anthrax.

The clinical relevance and importance of resistance mechanisms in strains of *B. anthracis* remains unclear. For example, certain strains of *B. anthracis* may produce beta-lactamases but administration of penicillin in animal models appears to prevent disease with these same strains. It is clear that microbiologic testing of isolates should be performed before and after drug exposure as part of the evaluation of products for prevention of inhalational anthrax. However, although the MICs for the extended-spectrum cephalosporins are not high, the efficacy of these drugs for the treatment of *B. anthracis* infection is unclear (Inglesby, et al., 1999).

**III. THE MONKEY MODEL — APPLICABILITY TO THE HUMAN DISEASE**

Because clinical studies of inhalational anthrax cannot be performed in humans (one cannot ethically intentionally expose patients to *B. anthracis* spores and randomize to active or placebo arms), the Agency has to rely on other evidence of efficacy for this indication. After much discussion and consideration, including input from the Anti-Infective Advisory Committee, the Agency believes that the use of the rhesus (macaque) monkey disease and treatment model for inhalational anthrax (post-exposure) provides convincing evidence of efficacy for regulatory purposes. The parallels, summarized here, between the rhesus monkey disease and treatment model and the human circumstance were noted by the Committee:

Exposure: The spores gained access to the respiratory tract via an aerosol as would be expected in human inhalational anthrax.

Antimicrobial use: The antimicrobials currently approved or found effective (ciprofloxacin, doxycycline, penicillin G procaine) were administered by the same route (oral or IM) and in the same q12h regimen in monkeys as was ultimately the recommended route and frequency in humans.

Antimicrobial Pharmacokinetics: For the drugs that have been granted regulatory approval for this indication, the peak and trough plasma concentrations measured in the rhesus model were similar to peak and trough plasma concentrations measured in humans.

196 Time course: The time course of the disease among untreated animals — short  
197 incubation, rapid down hill course, mortality — is similar to that among people who died  
198 of inhalational anthrax in Sverdlovsk in 1979 and in the United States in the fall of 2001.  
199

200 Histopathology: The autopsy findings of inhalational anthrax reported from the  
201 Sverdlovsk experience and reviewed by Dr. Walker at the July 28, 2000, Anti-Infective  
202 Advisory Committee meeting are strikingly similar to the necropsy findings reported by  
203 Dr. Friedlander in the monkeys that died of inhalational anthrax. Other published  
204 literature support these comparative histopathological findings. (Fritz et al, 1995; Gleiser  
205 et al, 1967.)  
206

207 Antimicrobial Activity in Monkey Model: For the drugs currently approved for this  
208 indication, the efficacy of the antimicrobial product (ciprofloxacin, doxycycline,  
209 penicillin G procaine) compared to saline placebo showed a statistically significant  
210 difference in favor of antimicrobial administration, whether one looked at the intent to  
211 treat analysis (all animals studied) or the per protocol analysis (anthrax deaths).  
212

213 A study indicating that another species of monkey was interchangeable with rhesus monkeys  
214 would be considered by the Agency. The data from a monkey study could be submitted as long  
215 as the model is used in conjunction with data from other sources, including:  
216

- 217 • in vitro sensitivity data on *B. anthracis*
- 218 • pharmacokinetic data in animals and in humans
- 219 • information on drug efficacy in treating other infections
- 220 • evidence of safety up to and exceeding 60 days  
221

222 This information, as well as convincing evidence from the rhesus monkey model, should be  
223 submitted in the application for approval.  
224

#### 225

#### 226 **IV. DRUGS EFFECTIVE IN MANAGING PATIENTS**

#### 227

228 On August 30, 2000, the Agency approved ciprofloxacin hydrochloride tablets, ciprofloxacin  
229 intravenous (IV) solution, ciprofloxacin IV in 5 percent dextrose, ciprofloxacin IV in 0.9 percent  
230 saline, and ciprofloxacin oral suspension for use in the management of patients who have been  
231 exposed to aerosolized spores of *B. anthracis* as a 60-day regimen. The new drug applications  
232 (NDAs) submitted by the sponsor for these products included in vitro activity information,  
233 pharmacokinetic data in humans and monkeys, long-term safety data on ciprofloxacin, and the  
234 results of an efficacy study in nonhuman primates. This information was brought before the  
235 Anti-Infective Advisory Committee with a recommendation for approval of the indication and a  
236 dosing duration of 60 days.<sup>3</sup>  
237

238 On November 2, 2001, in a public health response to the use of anthrax spores as a bioterrorism  
239 agent, the Agency published a notice in the *Federal Register* (66 FR 55679) that clarified the

---

<sup>3</sup> See transcript of meeting at <http://www.fda.gov/cder/drug/infopage/cipro/default.htm>.

240 dosing recommendations for doxycycline products and penicillin G procaine in the management  
241 of patients with inhalational anthrax who had been exposed to the spores of *B. anthracis*, but  
242 who did not manifest clinical disease.<sup>4</sup> Drug products containing doxycycline, doxycycline  
243 calcium, doxycycline hyclate, and penicillin G procaine had already been approved with  
244 indications for anthrax. The *Federal Register* notice stated that the Agency “determined that the  
245 language in the labeling of drug products containing doxycycline, doxycycline calcium,  
246 doxycycline hyclate, and penicillin G procaine is intended to, and does, cover all forms of  
247 anthrax, including inhalational anthrax (post-exposure): to reduce the incidence or progression  
248 of disease following exposure to aerosolized *B. anthracis*.” The *Federal Register* notice further  
249 requested that applicants for these products submit labeling supplements to update their package  
250 inserts with this information.

251  
252 It is relevant to the above information on ciprofloxacin, doxycycline, and penicillin G procaine  
253 that the rhesus monkey study supporting the approval of ciprofloxacin also included separate  
254 doxycycline and penicillin G procaine treatment arms. Each of these arms showed a survival  
255 advantage over placebo (Friedlander et al., 1993). No other antimicrobial drugs were tested in  
256 this study.<sup>5</sup>

257  
258 The *Federal Register* notice also explained that other drug products are currently approved with  
259 indications for anthrax or infections caused by *B. anthracis* (i.e., minocycline, tetracycline,  
260 oxytetracycline, demeclocycline, and penicillin G potassium), that data on these other drugs were  
261 undergoing review, and that additional data might be needed to make an explicit labeling  
262 recommendation for their use in inhalational anthrax (post-exposure). This notice served to guide  
263 the regulatory decisions regarding ciprofloxacin, doxycycline, and penicillin G procaine.

264  
265

## 266 **V. INHALATIONAL ANTHRAX (POST-EXPOSURE)**

267  
268 The safety and effectiveness of an antimicrobial to either prevent or treat disease following  
269 aerosolized exposure to *B. anthracis* cannot be tested in humans because the naturally occurring  
270 disease is rare, and it is unethical to expose humans to the bacteria intentionally. As a result, an  
271 application requesting approval of a drug for the indication INHALATIONAL ANTHRAX  
272 (POST-EXPOSURE) should contain the elements discussed in detail in this section. Studies  
273 planned and conducted as recommended in this guidance should yield the information necessary  
274 for the Agency to determine whether the antimicrobial under study is safe and effective in the  
275 management of this condition.

276  
277 This guidance serves as our best advice under the current scenario where approved therapies are  
278 available and the country is not in a state of massive-scale exposure to *B. anthracis*. In the event  
279 of a large-scale exposure or absence of other approved therapies (e.g., because supplies are  
280 exhausted or otherwise unavailable), the Agency would provide emergency guidance on an  
281 alternative approach.

---

<sup>4</sup> See information at [http://www.fda.gov/cder/drug/infopage/penG\\_doxy/default.htm](http://www.fda.gov/cder/drug/infopage/penG_doxy/default.htm) or [www.gpo.gov](http://www.gpo.gov).

<sup>5</sup> See July 28, 2000, Advisory Committee transcript <http://www.fda.gov/ohrms/dockets/ac/cder00.htm#Anti-Infective>.

282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325

Applications that can meet some of the elements listed below can request fast track designation while completing the development of data on the other elements.<sup>6</sup>

**A. The Indication: Regulatory Synonyms**

The Agency has determined that the indication should be designated INHALATIONAL ANTHRAX (POST-EXPOSURE) with further clarification that administration of an antimicrobial is intended “to reduce the incidence or progression of disease following exposure to aerosolized *B. anthracis*.”

Specifically, this means that drug administration should start *after* a known or suspected exposure to the aerosolized spores of *B. anthracis*, but *before* clinical symptoms of the disease develop. Some refer to this intended indication as *post-exposure prophylaxis* even though the intended administration of drug is after the exposure to *B. anthracis*.

The purpose of specifying this indication is to distinguish it from (1) the treatment of symptomatic, established inhalational anthrax infection, which is accompanied by a substantial morbidity and (2) prophylaxis of the disease, namely, administering the drug before exposure to *B. anthracis*.

**B. Chemistry**

There are no expected chemistry issues because it is anticipated that the drug product already will have been approved in the United States.

**C. Preclinical Toxicology Data**

It is anticipated that the drug product under development already will have been approved for marketing and that data are available in the approved NDA on animal toxicity in at least two species (e.g., rat, mouse, dog, monkey) for durations up to 6 months. If clinical data and experience demonstrate that a 60-day course of therapy would be reasonably safe to administer to humans, long-term animal toxicology data would not be necessary. (The drugs currently approved have been on the market from 10 to 50 years and already exceed 100 million treatment courses in the United States with additional experience worldwide.) Carcinogenicity studies may provide useful information, but are not necessary for the same reason.

**D. In Vitro Microbiology Data**

When ciprofloxacin was approved and the findings of efficacy published for doxycycline and penicillin G procaine, the available information on in vitro sensitivity of *B. anthracis* to these antimicrobials was extensive. The Agency had information on more than 90 isolates. When submitting a supplemental application for this indication, it would be

---

<sup>6</sup> See guidance for industry *Fast Track Drug Development Programs — Designation, Development, and Application Review* (September 1998).

326 reasonable to submit a smaller number of isolates, particularly if there is evidence that all  
327 isolates have uniformly low MICs to the drug of interest.

328  
329 **Note:** The term *low MICs* is used because the FDA and NCCLS have not established  
330 susceptibility breakpoints for this organism. Therefore, it would be inappropriate to state  
331 that the isolates are uniformly susceptible. The goal of the in vitro testing is to  
332 demonstrate that low concentrations of a drug (below those that could be achieved in  
333 dosing in humans) reliably inhibit growth of *B. anthracis*. Depending on the consistency  
334 and uniformity of MICs determined when testing a particular drug, it is possible that 30  
335 to 50 isolates would be adequate. With multiple-fold variability in the MIC results, data  
336 on a larger number of isolates should be submitted.

337  
338 In summary, we recommend the following:

- 339  
340 • Several strains (including Vollum, Ames, Sterne, and others) and multiple isolates  
341 (from 30 to 90, as discussed above) should be tested.
- 342  
343 • Testing should be done in at least two to three laboratories, and at least some of the  
344 same isolates should be tested by these laboratories to demonstrate reproducibility of  
MIC results.
- 345  
346 • During testing, ciprofloxacin, doxycycline and/or penicillin G should be used as  
control drugs.
- 347  
348 • All susceptibility testing should include a wide enough range of concentrations so that  
all MICs have an exact quantitative value instead of *< some value* or *> some value*.
- 349  
350 • The details of the testing should be documented (e.g., a protocol should be provided).
- 351  
352 • If antimicrobial resistance is detected, the mechanism should be characterized.
- 353  
354 • Efforts should be made to measure the potential for development of resistance in  
355 vitro. This testing should include studies to determine the frequency of spontaneous  
356 mutation and the emergence of multistep resistance in the presence of the compound.  
Another drug such as ciprofloxacin, doxycycline, or penicillin should be included as a  
comparator. Once such information is available, attempts should be made to correlate  
the mutation frequency with clinical outcome.
- 357  
358 • Studies to measure reciprocal cross-resistance should also be considered using other  
359 drugs such as ciprofloxacin, doxycycline, and penicillin G (the three drugs now found  
360 to be effective for post-exposure inhalational anthrax).

#### 361 **E. Rhesus Monkey and Other Animal Models of Efficacy**

362  
363 The Agency believes that until a better approach can be identified to approve drugs for  
364 use in persons exposed to aerosolized *B. anthracis*, the rhesus monkey model  
365 (Friedlander 1993) should be used for testing additional drugs. A study or data indicating  
366 that another species of monkey is interchangeable with rhesus monkeys would be  
367 considered by the Agency. The value of using this model is the similarity of (1) the  
368 disease, (2) the response to therapy, and (3) systemic drug exposure in the primate model  
369 when compared to humans. There also is value in replicating the efficacy results shown

370 in the original study. Study results should be available at the time the supplement is  
371 submitted, not as part of a phase 4 commitment.

372  
373 In summary, the following general recommendations should be followed:

- 374 • The drug should be tested in a nonhuman primate model.
- 375 • A vehicle control group should be included. This would serve as a negative control to  
376 determine the progression of disease in the absence of treatment.
- 377 • Consider using penicillin, doxycycline, and/or ciprofloxacin as a positive control.  
378 This approach can serve as an active control and provide for replication of results  
379 from the initial study conducted by Friedlander et al., (1993).
- 380 • At least 10 animals per arm should be studied.
- 381 • Treatment should continue for 30 days.
- 382 • There should be a 70-day follow-up observation period after treatment is completed,  
383 for a total study duration of 100 days.
- 384 • Specify dose and dosage regimen. Animal dosages should be determined based on  
385 the anticipated human dosage regimen. The animal dose should give systemic  
386 exposures comparable to the anticipated human exposure, and the drug regimen (e.g.,  
387 QD, BID) should be the same as anticipated in humans. In addition, periodic  
388 measurement of peak and trough levels should be done in animals during the study to  
389 confirm the level of drug exposure.
- 390 • The route of drug administration in animals should be applicable to human use.
- 391 • Blood samples for pharmacokinetic (PK) analysis should be collected from each  
392 drug-treated monkey. At a minimum, blood samples should be collected to determine  
393 plasma drug concentrations at the approximate time of maximum concentration (peak  
394 or Cmax) and at the end of the dosing interval (trough or Cmin), after first dose  
395 administration and for several successive days after steady state has been attained (at  
396 least 5 Cmax and 5 Cmin determinations).
- 397 • End points should include survival, bacteremia at different time intervals during or  
398 after treatment, and microbial burden in infected organs and/or tissues (e.g., blood,  
399 spleen, liver) collected at the time of necropsy.
- 400 • Bacteria cultured from animals that develop infection either on treatment or in the 60-  
401 day followup period should be tested for in vitro sensitivity to determine MICs. The  
402 MICs after treatment should be compared to the baseline values.
- 403 • Histopathology data on animals that died during the study should be recorded.
- 404 Applicants should also consider developing models using small animals (e.g., guinea  
405 pigs), which may be more readily available and which could be used for further study of  
406 drugs, drug dosing, drug regimens, and drug duration, as well as exploring drug regimens  
407 and drug combinations for treatment of established disease. Although not required, the  
408 development of such models would benefit public health by advancing the science and  
409 knowledge in the area of animal models for the study of disease caused by *B. anthracis*.
- 410

411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454

In addition, applicants may wish to explore the possibility of studies in other nonhuman primates such as cynomolgous or African green monkeys.

## **F. Clinical Pharmacology**

It is important to obtain complete pharmacokinetic data on the drug in human volunteers or patients and pharmacokinetic data in the rhesus monkey in the efficacy study of inhalational anthrax (post-exposure). The purpose of obtaining these data is to demonstrate that the desired systemic exposure achieved in humans after the anticipated dosage regimen can actually be achieved and is effective in the animal model in preventing inhalational anthrax infection and consequent mortality. Alternatively, it is important to demonstrate that the systemic exposure to the antimicrobial achieved in the rhesus monkey and found effective in preventing infection and death is an exposure that is achievable in humans with an approved and/or otherwise safe-to-use dosage.

In summary, we recommend the following:

- The doses to be tested in animals and in humans should be determined. A pharmacokinetic/pharmacodynamic (PK/PD) approach may be helpful in the determination of an appropriate dosage regimen. For example, use of PK/PD parameters such as AUC/MIC and/or C<sub>max</sub>/MIC may be useful for antimicrobial drugs with concentration-dependent mechanisms of bacterial killing, while the time above the MIC (T<sub>MIC</sub>) may be useful for antimicrobial drugs with time-dependent mechanisms of bacterial killing.
- The route of administration should be designated and should be the same in both monkeys and humans.
- Each of at least 10 monkeys should have both peak and trough plasma concentrations determined at least 5 times during the study.
- Because it is anticipated that the drug to be tested already will be on the market, adequate pharmacokinetic data should already be available in package labeling or in the literature. If such information is not available, the sponsor should provide pharmacokinetic data after single-dose and repeat-dose administration from an adequate number of male and female subjects for the purpose of providing descriptive statistics and to show comparable systemic drug exposure to that in the animal models used to study the drug for inhalational anthrax (post-exposure).
- Pharmacokinetic data for special populations, including pediatric patients, elderly subjects (≥65 years), and subjects with renal and hepatic impairment should be provided.
- Available pharmacokinetic data in pregnant women should be submitted.
- Available data for drug excretion into human breast milk should be submitted.



- 455
- 456
- 457
- 458
- 459
- 460
- 461
- 462
- 463
- 464
- 465
- 466
- 467
- 468
- Available pharmacokinetic data in the animals chosen for study of the drug for inhalational anthrax (post-exposure) and comparison of the pharmacokinetic and/or systemic exposure between the animals and humans should be submitted.
  - Full characterization of the metabolic profile (in vitro and in vivo) in humans and in the animals chosen to study the drug for inhalational anthrax (post-exposure) should be provided.
  - Information regarding the potential for pharmacokinetic drug interactions in humans should be submitted.
  - Information comparing the plasma protein binding of the drug in the chosen animals and in humans should be submitted.

### 469 **G. Efficacy in Humans for Other Indications**

470

471 It is expected that in the event of a large-scale exposure to anthrax, large numbers of  
472 people would be administered antimicrobials to prevent symptomatic infection by *B.*  
473 *anthracis*. As a result, the Agency recommends that drugs to be developed for this use  
474 already be on the market and already show their effectiveness in the treatment of a range  
475 of infectious diseases, which may include, but need not be limited to, respiratory,  
476 mediastinal, intra-abdominal, bone, or meningeal infections.

477  
478 In summary, we recommend the following:

- 479
- 480
- The drug to be evaluated should already be an approved *and marketed* drug.
  - The drug should be safe and effective in the treatment of a range of infectious diseases due to a variety of pathogens.

### 484 **H. Evidence of Long-Term Safety in Humans**

485

486 Because the anticipated duration of therapy for patients exposed to inhaled anthrax spores  
487 is at least 60 days, there should be sufficient data on prolonged use of the drug in large  
488 numbers of patients. The drug should have shown few and self-limited, or reversible,  
489 adverse events. For example, ciprofloxacin was initially approved in 1987. By the time  
490 of approval for inhalational anthrax (post-exposure) in 2000, the drug had been  
491 prescribed to at least 100 million patients for the treatment of other infections.  
492 Doxycycline and penicillin G procaine both have been on the worldwide market for more  
493 than 30 and 50 years, respectively.

494  
495 The sponsor should provide any data on adverse events that may be unique or more  
496 common with longer duration of dosing compared to shorter courses of therapy.  
497 In addition to long-term safety data, sponsors should provide marketing information on  
498 all applicable formulations, including solid oral dosage forms, pediatric oral dosage  
499 forms, and parenteral dosing forms.

500

501 Finally, the Agency is interested in reviewing all available data on the safety of the drug  
502 in relevant subpopulations, including geriatric patients, adults, the pediatric population,  
503 and pregnant women. Information on patients with kidney or renal impairment, as  
504 appropriate, also should be submitted.

505  
506 **I. Statistics**

507  
508 In the animal model to support approval, the antimicrobial drug must demonstrate  
509 efficacy, that is, it must be shown to be statistically superior to placebo (21 CFR 314.510  
510 and 314.126).

511  
512 **J. Regulatory Issues**

513  
514 Unless it already carries an anthrax indication (e.g., tetracycline class agents, aqueous  
515 penicillin G), the drug would be approved under § 314.500, Subpart H, accelerated  
516 approval. This approval would be based on the surrogate endpoint of the relationship  
517 between serum concentrations in humans and animals, in the context of the animal model  
518 of efficacy, as was the case for ciprofloxacin.

519  
520 **K. Labeling**

521  
522 Once the supplement has been approved, labeling should:

- 523
- 524 • List the organism in the in vitro microbiology subsection
  - 525 *Note:* The Agency does not believe including this particular organism in the in vitro  
526 section of the labeling in the absence of data supporting approval of the indication is  
527 appropriate.
  - 528 • List the indication (e.g., inhalational anthrax (post exposure))
  - 529 • Provide the appropriate dosing regimen
  - 530 • Provide the regulatory information forming the basis of approval
  - 531 • Provide a summary of the data that served as the basis of approval
- 532

533 **L. Postapproval Commitments and/or Requirements**

534  
535 Because it is anticipated that these drugs would be approved for inhalational anthrax  
536 (post-exposure) under Subpart H regulations (§ 314.500), the approval letter would  
537 request that confirmatory clinical data be provided in the event of an accidental or  
538 intentional exposure to aerosolized *B. anthracis* (§ 314.510). Applicants should include  
539 as part of their application a plan or approach to obtaining such confirmatory data in the  
540 event such studies become ethical and feasible as a result of such an exposure. Among  
541 other information, relevant data would include patient identifying information, a listing of  
542 the drugs that were used, and data on compliance, adverse reactions, and outcomes.  
543 Sponsors may wish to consult with the division about the contents of their postmarketing  
544 study plan before submission to the Agency. In addition, the company would agree to  
545 cooperate with relevant U.S.-based public health agencies in the collection and evaluation

546 of data on the use of the drug product in a large U.S. population exposed to *B. anthracis*,  
547 should such an exposure occur.

548  
549 Under Subpart H regulations, the company also would have to have any advertising or  
550 promotional material for this indication cleared by the Agency before use (§ 314.550).

551  
552  
553 **VI. SUMMARY**

554  
555 In summary, we recommend that the applicant provide information on the following:

- 556  
557 • In vitro antimicrobial sensitivity data on an adequate number of isolates, reflecting the  
558 spectrum of available isolates and taking into consideration the possibility of engineered  
559 resistant strains
- 560 • Clinical pharmacology data on the proposed dosing regimen of the product
- 561 • Safety data, including preclinical and clinical dose and duration data that support the use  
562 of this product for long durations up to at least 60 days
- 563 • Evidence of extensive use of the product including use in geriatric patients, adults, the  
564 pediatric population, pregnant women, and any other special populations
- 565 • Efficacy data in humans. Priority will be given to drugs that have been approved for a  
566 variety of indications and have a fairly substantial marketing history.
- 567 • Efficacy, pharmacokinetic and histopathology data from nonhuman primate models of  
568 inhalational anthrax. Efficacy data should be submitted based on a study of the  
569 antimicrobial in a nonhuman primate model of inhalational anthrax that replicates the  
570 Friedlander study. Other animal models may be used once the Friedlander study has  
571 been replicated successfully with studies of other antimicrobials for inhalational anthrax  
572 (post-exposure) and those animal models have been validated. Other animal models  
573 could include nonhuman primates other than rhesus monkeys and smaller animals. The  
574 ultimate goal of such studies is to find a small animal model with more readily available  
575 animals to replace the rhesus monkey model so that more specific and detailed testing of  
576 dosing, duration, and combinations can be done.

577

578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619

## REFERENCES

Centers for Disease Control and Prevention (CDC), 2000, "Human Anthrax Associated with an Epizootic Among Livestock – North Dakota," *MMWR.*, 50(32):677-680.

Brachman, P. S., 1980, "Inhalational Anthrax," *Ann NY Acad Sci.*, 353:83-93.

Friedlander, A. M., S. L. Welkos, M. L. M. Pitt, et al., 1993, "Post-Exposure Prophylaxis Against Experimental Inhalation Anthrax," *J Infect Dis.*, 167:1239-1242.

Fritz, D.L., Jaax, N.K., Lawrence, W.B., et al. 1995, "Pathology of Experimental Inhalation Anthrax in the Rhesus Monkey," *Lab Invest.*, 73:691-702

Gleiser, C.A., 1967, "Pathology of Anthrax Infection in Animal Hosts," *Fed Proc.*, 26:1518-1521.

Henderson, D. W., S. Peacock, and F. C. Belton, 1956, "Observations on the Prophylaxis of Experimental Pulmonary Anthrax in the Monkey," *J. Hyg.*, 54:28-36.

Inglesby, T. V., D. A Henderson, J. G. Bartlett, et al., 1999, "Anthrax As a Biological Weapon," *JAMA*, 281(18):1735-1745.

Lightfoot, N.F., R.J.D. Scott, and P.C.B. Turnbull, 1990, "Antimicrobial Susceptibility of *Bacillus anthracis*," *Salisbury Med Bull.*, 68 special supplement:95-98.

Meselson, M., J. Guillemin, M. Hugh-Jones, et al., 1994, "The Sverdlovsk Anthrax Outbreak of 1979," *Science*, 266:1202-1208.

National Committee for Clinical Laboratory Standards, 2000, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Fifth Edition*, M7-A5, 20: No. 2.

Plotkin, S. A., P. S. Brachman, M. Utell, et al., 1960, "An Epidemic of Inhalational Anthrax, the First in the Twentieth Century," *Am J Med*, 29:992-1001.

Stepanov, A. V., L. I. Marinin, A. P. Pomerantsev, et al., 1996, "Development of Novel Vaccines Against Anthrax in Man," *J Biotechnol.*, 44:155-160.

Suffin, S. C., W. H. Carnes, A. F. Kaufmann, et al., 1978, "Inhalational Anthrax in a Home Craftsman," *Human Pathology*, 9(5):594-597.